3 completed, 1 not yet recruiting, 1 unknown. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
Follow HTX-011: new trials by email Literature Review of HTX-011 trials Research Report on HTX-011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zynrelef Versus Adductor Canal Block ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution - Knee Osteoarthritis, Arthritis Knee | Phase 4 | Not yet recruiting | University of Miami | 120 | 2027-01-01 | 2026-06-12 |
| Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty HTX-011, ropivacaine , epinephrine , ketorolac diluted in sodium chloride - Total Knee Arthroplasty | Phase 4 | Completed | Mayo Clinic | 209 | 2022-03-11 | 2025-04-27 |
| Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) HTX-011, Bupivacaine Hydrochloride, MMA regimen - Postoperative Pain, Total Shoulder Arthroplasty | Phase 4 | Completed | Heron Therapeutics | 30 | 2021-10-20 | 2026-10-27 |
| A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. Bupivacaine Hydrochloride, HTX-011, Luer lock applicator - Analgesia | Phase 4 | Unknown | Heron Therapeutics | 90 | 2021-10-12 | 2023-10-26 |
| Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) MMA regimen, ZYNRELEF kit components for administration, HTX-011 - Postoperative Pain, Abdominoplasty Surgery | Phase 4 | Completed | Heron Therapeutics | 37 | 2021-10-12 | 2026-10-28 |
Pain, Postoperative (3) · Agnosia (1) · Osteoarthritis, Knee (1)
Heron Therapeutics (3) · Mayo Clinic (1) · University of Miami (1)
United States (5)
Colin A. McNamara, MD,MBA (1) · Matthew P Abdel, MD (1)